SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel Post author: Post published:December 12, 2023 Post category:uncategorized SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study. You Might Also Like New funding to strengthen stroke care systems in Minnesota and South Dakota October 10, 2024 Tattoos could be a risk factor for lymphoma, study suggests May 24, 2024 New antifungal molecule shows promise in combatting fungal infections without toxicity November 9, 2023
New antifungal molecule shows promise in combatting fungal infections without toxicity November 9, 2023